Glasshouse Plots for VMware IPO Sequel, Idera Partners With Merck, iRobot Inks Deal With Army, & More

12/24/07

Ho, ho, holy cow there were a lot of deals last week! In case you missed any on account of snow-shoveling, shopping, or hall-decking, here’s a recap:

—Bristol-Myers Squibb (NYSE: BMY) agreed to sell its Billerica, MA-based medical imaging division to private equity firm Avista Capital Partners for some $525 million.

—Burlington, MA’s iRobot (NASDAQ: IRBT) inked a deal worth up to $286 million to supply bomb-detection robots to the Army. The deal came in the midst of a certain amount of, let’s say, drama.

—Second Wind, a Somerville, MA-based maker of “sodar” devices for measuring wind conditions, announced a $4 million second-round financing from renewable energy investor Good Energies.

—Brookfield, CT’s Validus DC Systems raised a first round, worth $10 million, from a syndicate led by Oak Hill Venture Partners.

—Library-management-software firm Inmagic of Woburn, MA, announced a $5 million investment from New Jersey-based Edison Venture Fund.

—Framingham, MA-based GlassHouse Technologies stuck its toe in the virtualization IPO waters that VMware recently found so warm by registering for an IPO worth up to $100 million.

—Nuance Communications (NASDAQ: NUAN) of Burlington, MA cut size of its planned secondary stock offering almost in half.

—Cambridge, MA-based Elixir Pharmaceuticals set the price range for its 5 million share IPO at between $14 and $16 per share.

—North Andover, MA-based Acquia, which aims to market software and services built around the open-source Web publishing system Drupal, raised $7 million in a first round of financing led by North Bridge Venture Partners.

—Idera Pharmaceuticals (NASDAQ: IDRA) forged a drug-development deal potentially worth more than $400 million with Germany’s Merck KGaA.

—Altus Pharmaceuticals (NASDAQ:ALTU) took a stock-market nosedive after announcing its deal with Genentech around a human growth hormone deal has lapsed.

By posting a comment, you agree to our terms and conditions.

  • swoit